U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185672) titled 'PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)' on Aug. 25.
Brief Summary: Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas. Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the established standard of care for patients with well-differentiated metastatic or locally advanced GEP-NETs. It has demonstrated a significant improvement in outcomes compared to Octreotide LAR, both as a first-line and second-line treatment approach, following the results of NETTER-1 an...